Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.

Dokumenttyp:: Clinical Trial, Phase II; Letter; Multicenter Study; Research Support, Non-U.S. Gov't; Letter
Autor(en):: Elter, T; James, R; Busch, R; Winkler, D; Ritgen, M; Böttcher, S; Kahl, C; Gassmann, W; Stauch, M; Hasan, I; Staib, P; Fischer, K; Fink, AM; Bahlo, J; Bühler, A; Döhner, H; Wendtner, CM; Stilgenbauer, S; Engert, A; Hallek, M
Titel:: Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Zeitschriftentitel:: Leukemia
Jahr:: 2012
Band / Volume:: 26
Heft / Issue:: 12
Seitenangaben Beitrag:: 2549-52
Sprache:: eng
Volltext / DOI:: doi:10.1038/leu.2012.129
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/22584787
Print-ISSN:: 0887-6924
TUM Einrichtung:: Institut für Medizinische Statistik und Epidemiologie
BibTeX

Vorkommen: